============================================================================
============================================================================




                    SECURITIES AND EXCHANGE COMMISSION
                           Washington, DC 20549



                                FORM 10-Q


                Quarterly Report Under Section 13 or 15(d)
                  of the Securities Exchange Act of 1934






FOR QUARTER ENDED SEPTEMBER 30, 2001        COMMISSION FILE NUMBER 0-8640



                     SYNCOR INTERNATIONAL CORPORATION
          (Exact name of registrant as specified in its charter)


           DELAWARE                                  85-0229124
(State or other jurisdiction of        (I.R.S. Employer Identification No.)
 incorporation or organization)


6464 CANOGA AVENUE, WOODLAND HILLS, CALIFORNIA          91367
   (Address of principal executive offices)           (Zip Code)


                               (818) 737-4000
            (Registrant's telephone number, including area code)


Indicate by check mark whether the Registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period
that the Registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days.

                         Yes  X   No
                             ___     ___


Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date.  As of
September 30, 2001, 24,761,491 shares of $.05 par value common stock
were outstanding.


============================================================================
============================================================================
<PAGE>

           SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES

                                INDEX
                                _____



                                                                          Page
                                                                          ____
Part I.    Financial Information

  Item 1.  Condensed Consolidated Financial Statements

       Balance Sheets as of
         September 30, 2001 and December 31, 2000............................3

       Statements of Income for Three Months
         Ended September 30, 2001 and 2000...................................4

       Statements of Income for Nine Months
         Ended September 30, 2001 and 2000...................................5

       Statements of Cash Flows for Nine Months
         Ended September 30, 2001 and 2000...................................6

       Notes to Condensed Consolidated Financial Statements..................7

  Item 2.  Management's Discussion and Analysis of Financial Condition......12

  Item 3.  Quantitative and Qualitative Disclosures about Market Risk.......14

Part II.   Other Information................................................15

SIGNATURE...................................................................16

<PAGE>

ITEM 1.

<TABLE>
<CAPTION>

             SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
                   Condensed Consolidated Balance Sheets
                              (in thousands)

                                                     September 30, December 31,
                                                          2001        2000
                                                     _____________ ____________
                                                      (Unaudited)
<S>                                                    <C>          <C>
ASSETS
Current assets:
  Cash and cash equivalents                            $ 25,607     $ 24,330
  Short-term investments                                 11,381        4,156
  Trade receivables, net                                108,032       81,716
  Patient receivables, net                               50,362       37,686
  Inventory                                              22,828       59,926
  Prepaids and other current assets                      30,372       16,023
                                                      __________   __________

     Total curent assets                                248,582      223,837

Marketable investment securities                          1,209        1,190
Property and equipment, net                             168,697      114,286
Excess of purchase price over net assets acquired, net  133,846      108,530
Other assets                                             18,468       22,728
                                                      __________   __________

                                                       $570,802     $470,571
                                                      ==========   ==========

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
  Accounts payable                                     $ 59,312     $ 83,683
  Accrued liabilities                                    24,156       22,371
  Accrued wages and related costs                        15,315       19,796
  Federal and state taxes payable                         6,560        5,543
  Current maturities of long-term debt                   10,753       12,091
                                                      __________   __________

     Total current liabilities                          116,096      143,484

Long-term debt, net of current maturities               220,163      137,886
Deferred taxes                                            6,243        3,321

Stockholders' equity:
  Common stock, $.05 par value                            1,412        1,376
  Additional paid-in capital                            123,444      107,268
  Notes receivable-related parties                       (6,998)     (16,796)
  Employee stock ownership loan guarantee                  (421)      (1,685)
  Accumulated other comprehensive income                 (1,195)      (1,245)
  Retained earnings                                     143,042      114,019
  Treasury stock, at cost; 3,483 shares at September
     30, 2001 and 3,072 shares at December 31, 2000     (30,984)     (17,057)
                                                      __________   __________

     Net stockholders' equity                           228,300      185,880
                                                      __________   __________

                                                       $570,802     $470,571
                                                      ==========   ==========

</TABLE>

SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

<PAGE>

             SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
                Condensed Consolidated Statements of Income
                                (Unaudited)
                   (in thousands, except per share data)


<TABLE>
<CAPTION>

                                              THREE MONTHS ENDED SEPTEMBER 30,
                                                    2001              2000
                                                   ______            ______

<S>                                               <C>               <C>
Net sales                                         $193,794          $155,462

Cost of sales                                      121,005           100,044
                                                  _________         _________

  Gross profit                                      72,789            55,418

Operating, selling and administrative expenses      47,100            36,191

Depreciation and amortization                       10,317             6,951
                                                  _________         _________

  Operating income                                  15,372            12,276

Other expense, net                                  (2,527)           (1,857)
                                                  _________         _________

Income before taxes                                 12,845            10,419

Provision for income taxes                           5,011             4,161
                                                  _________         _________

Net income                                        $  7,834          $  6,258
                                                  =========         =========


Net income per share - Basic                         $ .32             $ .26
                                                  =========         =========


Weighted average shares outstanding - Basic         24,603            24,091
                                                  =========         =========


Net income per share - Diluted                       $ .29             $ .23
                                                  =========         =========

Weighted average shares outstanding - Diluted       27,024            27,374
                                                  =========         =========


</TABLE>

SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

<PAGE>

             SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
                Condensed Consolidated Statements of Income
                                (Unaudited)
                   (in thousands, except per share data)


<TABLE>
<CAPTION>

                                             NINE MONTHS ENDED SEPTEMBER 30,
                                                    2001          2000
                                                   ______        ______

<S>                                               <C>           <C>
Net sales                                         $562,902      $458,786

Cost of sales                                      349,245       296,931
                                                  ________      ________

  Gross profit                                     213,657       161,855

Operating, selling and administrative expenses     127,918       101,144

Depreciation and amortization                       28,017        18,721
                                                  ________      ________

  Operating income                                  57,722        41,990

Other expense, net                                 (10,143)       (3,965)
                                                  ________      ________

Income before taxes                                 47,579        38,025

Provision for income taxes                          18,556        15,209
                                                  ________      ________

Net income                                        $ 29,023      $ 22,816
                                                  ========      ========


Net income per share - Basic                        $ 1.18         $ .96
                                                  ========      ========


Weighted average shares outstanding - Basic         24,494        23,864
                                                  ========      ========


Net income per share - Diluted                      $ 1.07         $ .86
                                                  ========      ========

Weighted average shares outstanding - Diluted       27,047        26,543
                                                  ========      ========

</TABLE>


SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

<PAGE>

             SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
              Condensed Consolidated Statements of Cash Flows
                                (Unaudited)
                              (in thousands)

<TABLE>
<CAPTION>

                                               NINE MONTHS ENDED SEPTEMBER 30,
                                                      2001         2000
                                                     ______       ______
Cash flows from operating activities:

<S>                                                  <C>           <C>
Net income                                           $29,023       $22,816
Adjustments to reconcile net income to net
cash provided by operating activities:
  Depreciation and amortization                       28,017        18,721
  Provision for losses on receivables                  6,283         4,307
  Amortization of ESSOP loan guarantee                 1,264         1,263
  Decrease (increase) in:
     Accounts receivable, trade                     (24,016)        (8,014)
     Accounts receivable, patient                   (12,676)       (13,901)
     Inventory                                       43,815        (15,139)
     Other current assets                           (12,133)        (5,631)
     Other assets                                     7,517         (3,443)
  Increase (decrease) in:
     Accounts payable                               (27,123)        20,157
     Accrued liabilities                              1,291          3,257
     Accrued wages and related costs                 (4,639)          (536)
     Federal and state taxes payable                  5,604         (1,496)
                                                    ________       ________

  Net cash provided by operating activities          42,227         22,361
                                                    ________       ________

Cash flows from investing activities:

  Purchase of property and equipment, net           (46,332)       (18,461)
  Acquisitions of businesses, net of cash acquired  (52,015)       (42,535)
  Net increase in short-term investments             (7,225)        (3,080)
  Net increase (decrease) in long-term investments      (19)             1
  Unrealized gain on investments                         20            133
                                                    ________       ________

  Net cash used in investing activities            (105,571)       (63,942)
                                                    ________       ________

Cash flow from financing activities:

  Proceeds from long-term debt                       65,337         37,279
  Repayment of long-term debt                        (8,212)        (3,174)
  Note receivable-related parties                     9,798          1,341
  Issuance of common stock                           11,625         14,362
  Reacquisition of common stock for treasury        (13,927)        (3,451)
                                                    ________       ________

  Net cash provided by financing activities          64,621         46,357
                                                    ________       ________

  Net increase in cash and cash equivalents           1,277          4,776

  Effect of exchange rate on cash                         -            (85)

  Cash and cash equivalents at beginning of period   24,330         13,352
                                                    ________       ________

  Cash and cash equivalents at end of period        $25,607        $18,043
                                                    ========       ========

</TABLE>

SEE NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.

<PAGE>

             SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
           Notes to Condensed Consolidated Financial Statements


1. GENERAL.  The accompanying unaudited condensed consolidated financial
   statements have been prepared in accordance with accounting principles
   generally accepted in the United States of America for interim financial
   information and with the instructions to Form 10-Q.  Accordingly, they
   do not include all of the information and footnotes required by accounting
   principles generally accepted in the United States of America for complete
   financial statements.  In the opinion of management, all adjustments
   (consisting only of normal recurring accruals) considered necessary for a
   fair presentation have been included. The results for the nine months
   ended September 30, 2001, are not necessarily indicative of the results to
   be expected for the full year.  For further information, refer to the
   consolidated financial statements and footnotes thereto included in our
   Annual Report on Form 10-K for the year ended December 31, 2000. Certain
   line items in the prior year's consolidated condensed financial statements
   have been reclassified to conform to the current year's presentation.


2. NEW ACCOUNTING STANDARDS.  In July 2001, the FASB issued Statement No.
   141, Business Combinations, and Statement No. 142, Goodwill and Other
   Intangible Assets.  Statement 141 requires that the purchase method of
   accounting be used for all business combinations initiated after June
   30, 2001 as well as all purchase method business combinations completed
   after June 30, 2001.  Statement 141 also specifies criteria intangible
   assets acquired in a purchase method business combination must meet to
   be recognized and reported apart from goodwill, noting that any purchase
   price allocable to an assembled workforce may not be accounted for
   separately.  Statement 142 will require that goodwill and intangible
   assets with indefinite useful lives no longer be amortized, but instead
   tested for impairment at least annually in accordance with the
   provisions of Statement 142.  Statement 142 will also require that
   intangible assets with definite useful lives be amortized over their
   respective estimated useful lives to their estimated residual values,
   and reviewed for impairment in accordance with SFAS No. 121, Accounting
   for the Impairment of Long-Lived Assets and for Long-Lived Assets to Be
   Disposed Of.

   The Company is required to adopt the provisions of Statement 141
   immediately, except with regard to business combinations initiated prior
   to July 1, 2001, which it expects to account for using the pooling-of-
   interests method, and Statement 142 effective January 1, 2002.*
   Furthermore, any goodwill and any intangible asset determined to have an
   indefinite useful life that are acquired in a purchase business
   combination completed after June 30, 2001 will not be amortized, but
   will continue to be evaluated for impairment in accordance with the
   appropriate pre-Statement 142 accounting literature.  Goodwill and
   intangible assets acquired in business combinations completed before
   July 1, 2001 will continue to be amortized prior to the adoption of
   Statement 142.

   Statement 141 will require upon adoption of Statement 142, that the
   Company evaluate its existing intangible assets and goodwill that were
   acquired in a prior purchase business combination, and to make any
   necessary reclassifications in order to conform with the new criteria in
   Statement 141 for recognition apart from goodwill.  Upon adoption of
   Statement 142, the Company will be required to reassess the useful lives
   and residual values of all intangible assets acquired in purchase
   business combinations, and make any necessary amortization period
   adjustments by the end of the first interim period after adoption.  In
   addition, to the extent an intangible asset is identified as having an
   indefinite useful life, the Company will be required to test the
   intangible asset for impairment in accordance with the provisions of
   Statement 142 within the first interim period.  Any impairment loss will
   be measured as of the date of adoption and recognized as the cumulative
   effect of a change in accounting principle in the first interim period.

   In connection with the transitional goodwill impairment evaluation,
   Statement 142 will require the Company to perform an assessment of
   whether there is an indication that goodwill is impaired as of the date
   of adoption.  To accomplish this the Company must identify its reporting
   units and determine the carrying value of each reporting unit by
   assigning the assets and liabilities, including the existing goodwill
   and intangible assets, to those reporting units as of the date of
   adoption.  The Company will then have up to six months from the date of
   adoption to determine the fair value of each reporting unit and compare
   it to the reporting unit's carrying amount.  To the extent a reporting
   unit's carrying amount exceeds its fair value, an indication exists that
   the reporting unit's goodwill may be impaired and the Company must
   perform the second step of the transitional impairment test.

   ______________________
*  Companies with fiscal year ends beginning after March 15, 2001, who have
   not yet issued financial statements for their first interim period, may
   early adopt Statement 142.

<PAGE>

   In the second step, the Company must compare the implied fair value of
   the reporting unit's goodwill, determined by allocating the reporting
   unit's fair value to all of its assets (recognized and unrecognized) and
   liabilities in a manner similar to a purchase price allocation in
   accordance with Statement 141, to its carrying amount, both of which
   would be measured as of the date of adoption.   This second step is
   required to be completed as soon as possible, but no later than the end
   of the year of adoption.  Any transitional impairment loss will be
   recognized as the cumulative effect of a change in accounting principle
   in the Company's statement of earnings.

   As of the date of adoption, the Company expects to have unamortized
   goodwill in the amount of $132,472, unamortized identifiable intangible
   assets in the amount of $7,112, all of which will be subject to the
   transition provisions of Statements 141 and 142.  Amortization expense
   related to goodwill was $3,793 and $4,456 for the year ended December
   31, 2000 and the nine months ended September 30, 2001, respectively.
   Because of the extensive effort needed to comply with adopting
   Statements 141 and 142, it is not practicable to reasonably estimate the
   impact of adopting these Statements on the Company's financial
   statements at the date of this report, including whether any
   transitional impairment losses will be required to be recognized as the
   cumulative effect of a change in accounting principle.

   In August 2001, the Financial Accounting Standards Board issued FASB
   Statement No. 144, Accounting for the Impairment or Disposal of Long-
   Lived Assets (Statement 144), which supersedes both FASB Statement
   No. 121, Accounting for the Impairment of Long-Lived Assets and for
   Long-Lived Assets to Be Disposed Of (Statement 121) and the accounting
   and reporting provisions of APB Opinion No. 30, Reporting the Results
   of Operations-Reporting the Effects of Disposal of a Segment of a
   Business, and Extraordinary, Unusual and Infrequently Occurring Events
   and Transactions (Opinion 30), for the disposal of a segment of a
   business (as previously defined in that Opinion).  Statement 144
   retains the fundamental provisions in Statement 121 for recognizing and
   measuring impairment losses on long-lived assets held for use and
   long-lived assets to be disposed of by sale, while also resolving
   significant implementation issues associated with Statement 121.
   Statement 144 retains the basic provisions of Opinion 30 on how to
   present discontinued operations in the income statement but broadens
   that presentation to include a component of an entity (rather than a
   segment of a business).  Unlike Statement 121, an impairment assessment
   under Statement 144 will never result in a write-down of goodwill.
   Rather, goodwill is evaluated for impairment under Statement No. 142,
   Goodwill and Other Intangible Assets.

   The Company is required to adopt Statement 144 no later than the
   year beginning after December 15, 2001.  Accordingly, the Company
   will adopt Statement 144 in the first quarter of 2002.  Management
   does not expect the adoption of Statement 144 for long-lived assets
   held for use to have a material impact on the Company's financial
   statements because the impairment assessment under Statement 144 is
   largely unchanged from Statement 121.  The provisions of the
   Statement for assets held for sale or other disposal generally are
   required to be applied prospectively after the adoption date to
   newly initiated disposal activities.  Therefore, management cannot
   determine the potential effects that adoption of Statement 144 will
   have on the Company's financial statements.

3. COMPREHENSIVE INCOME.  Other comprehensive income includes foreign
   currency translation adjustments and net unrealized gains and losses on
   investments in equity securities. Such amounts are as follows:

<PAGE>

<TABLE>
<CAPTION>
                                                      THREE MONTHS ENDED
                                                      __________________

                                     September 30, 2001                September 30, 2000
                                     __________________                __________________
                             Before-tax     Tax      Net-of-Tax  Before-Tax     Tax   Net-of-Tax
                               Amount     Expense      Amount      Amount     Expense   Amount
                             ____________________________________________________________________

<S>                               <C>         <C>        <C>         <C>         <C>        <C>
Foreign currency translation
  adjustments                      87          -          87         260          -         260

Unrealized gains (losses) on
  investments:
    Unrealized holding gains
    (losses) arising during
    period                         28        (11)         17           -          -          -
                             ____________________________________________________________________
Other comprehensive income        115        (11)        104         260          -        260

  Net income                   12,845     (5,011)      7,834      10,419     (4,161)     6,258
                               ______     _______      _____      ______     _______     _____

  Total comprehensive income  $12,960    $(5,022)     $7,938     $10,679    $(4,161)    $6,518
                              =======    ========     ======     =======    ========    ======


                                                      NINE MONTHS ENDED
                                                      _________________

                                     September 30, 2001                September 30, 2000
                                     __________________                __________________
                             Before-tax     Tax     Net-of-Tax  Before-Tax      Tax   Net-of-Tax
                               Amount     Expense     Amount      Amount      Expense   Amount
                             ____________________________________________________________________

<S>                              <C>          <C>        <C>        <C>         <C>        <C>
Foreign currency translation
  adjustments                     30           -          30        351          -         351

Unrealized gains (losses) on
  investments:
    Unrealized holding gains
    (losses) arising during
    period                        32         (12)         20        222        (89)        133
                             ____________________________________________________________________
Other comprehensive income        62         (12)         50        573        (89)        484

  Net income                  47,579     (18,556)     29,023     38,025    (15,209)     22,816
                              ______     ________     ______     ______    ________     ______

  Total comprehensive income $47,641    $(18,568)    $29,073    $38,598   $(15,298)    $23,300
                             =======     ========    =======    =======    ========     ======
</TABLE>

<PAGE>

4. SEGMENT INFORMATION. Syncor has identified three primary operating
   segments: U.S. Pharmacy Services, U.S. Medical Imaging and International
   Operations. Segment selection was based upon internal organizational
   structures, the process by which these operations are managed and
   evaluated, the availability of separate financial results, and materiality
   considerations. Segment detail is summarized as follows:

<TABLE>
<CAPTION>

                                                THREE MONTHS ENDED
                                                __________________
   U.S. Pharmacy Services Business    September 30, 2001   September 30, 2000
   _______________________________    __________________   __________________

   <S>                                      <C>                 <C>
     Revenues                               $142,284            $120,858
     Operating Income                       $ 15,358            $ 12,997

   U.S. Medical Imaging Business
   _____________________________

     Revenues                               $ 39,432            $ 26,475
     Operating Income                       $  4,228            $  3,251

   International Operations
   ________________________

     Revenues                               $ 12,078            $  8,129
     Operating Income                       $    342            $    388

   Unallocated Corporate
   _____________________

     Operating Loss                         $ (4,556)           $ (4,360)



                                                  NINE MONTHS ENDED
                                                  _________________
   U.S. Pharmacy Services Business    September 30, 2001   September 30, 2000
   _______________________________    __________________   __________________

   <S>                                      <C>                 <C>
     Revenues                               $413,308            $366,791
     Operating Income                       $ 55,525            $ 44,482

   U.S. Medical Imaging Business
   _____________________________

     Revenues                               $116,243            $ 66,943
     Operating Income                       $ 12,518            $  8,062

   International Operations
   ________________________

     Revenues                               $ 33,351            $  25,052
     Operating Income                       $  1,554            $   1,615

   Unallocated Corporate
   _____________________

     Operating Loss                         $(11,875)           $ (12,169)

</TABLE>


5. NET INCOME PER SHARE.  Basic earnings per share (EPS) amounts are
   computed by dividing earnings applicable to common stockholders by the
   weighted average number of shares outstanding. Diluted EPS amounts assume
   the issuance of common stock for all potentially dilutive equivalents
   outstanding.  Anti-dilutive outstanding stock options of 2,309 and zero for
   the three months and 2,307 and 779 for the nine months ended September 30,
   2001 and 2000 have been excluded from the diluted calculation, respectively.

   The reconciliation of the numerator and denominators of the basic and
   diluted earnings per share computations are as follows for the three and
   nine months ended September 30, 2001 and 2000:

<PAGE>

<TABLE>
<CAPTION>
                                                  THREE MONTHS ENDED
                                                  __________________
                               September 30, 2001                    September 30, 2000
                     __________________________________________________________________________
                        Income       Shares     Per Share     Income        Shares    Per Share
                     (Numerator)  (Denominator)   Amount    (Numerator)  (Denominator)  Amount
   ____________________________________________________________________________________________

   <S>                  <C>          <C>           <C>        <C>            <C>         <C>
   Net income           $7,834                                $6,258

   Basic EPS            $7,834       24,603        $.32       $6,258         24,091      $.26
                                                   ____                                  ____

   Effect of Dilutive
       Stock Options                  2,421                                   3,283
                                      _____                                   _____

   Diluted EPS          $7,834       27,024        $.29       $6,258         27,374      $.23
                                                   ____                                  ____


                                                  NINE MONTHS ENDED
                                                  _________________
                               September 30, 2001                    September 30, 2000
                     __________________________________________________________________________
                        Income       Shares     Per Share     Income        Shares    Per Share
                     (Numerator)  (Denominator)   Amount    (Numerator)  (Denominator)  Amount
   ____________________________________________________________________________________________

   <S>                 <C>           <C>          <C>         <C>            <C>         <C>
   Net income          $29,023                                $22,816

   Basic EPS           $29,023       24,494       $1.18       $22,816        23,864      $.96
                                                  _____                                  ____

   Effect of Dilutive
       Stock Options                  2,553                                   2,679
                                      _____                                   _____

   Diluted EPS         $29,023       27,047       $1.07       $22,816        26,543      $.86
                                                  _____                                  ____
</TABLE>


6. NOTES RECEIVABLE-RELATED PARTIES.  We initiated a Senior Management
   Stock Purchase Plan effective June 16, 1998, pursuant to which our
   officers and key employees purchased shares of Syncor stock.  The shares
   were paid with a five-year interest bearing promissory note payable to
   us.  Interest on each note is payable on each anniversary date, with the
   entire outstanding principal and unpaid interest due on the fifth
   anniversary date.


7. ACQUISITION OF BUSINESSES.  During the third quarter of 2001, we made
   four acquisition investments. We acquired a company that provides
   cardiovascular services through three sites in North Carolina and
   Virginia for a purchase price of $13.8 million. For the second
   acquisition, we acquired two domestic companies that design, manufacture
   and sell radiation detection and measurement equipment for the medical
   and nuclear power plant industry for a purchase price of $10.8 million.
   In addition, our medical imaging business acquired three centers via two
   acquisitions in the quarter. The first of these was a multi-MRI site in
   Ft. Lauderdale, Florida for a purchase price of $5.1 million plus the
   assumption of $1.5 million of debt. Secondly, we acquired two MRI centers
   in El Paso, Texas for a purchase price of $4.3 million plus the
   assumption of $3.6 million of debt.

<PAGE>

ITEM 2.


             SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES
        MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
                         AND RESULTS OF OPERATIONS
      FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2001 AND 2000


NET SALES
_________

Consolidated net sales for the three months ended September 30, 2001
increased 24.7% or $38.3 million to $193.8 million versus $155.5 million
for the third quarter of 2000.  Consolidated net sales for the nine months
ended September 30, 2001 increased 22.7% or $104.1 million to $562.9 million
versus $458.8 million for the same period of the prior year.

U.S. PHARMACY SERVICES BUSINESS

Our Pharmacy Services business grew year-over-year 17.7% to $142.3
million for the current quarter and 12.7% year-to-date to $413.3 million.
This increase is primarily the result of continued growth in both the
overall marketplace and the Cardiology sector of the Company's business.
In addition, our acquisitions accounted for $5.7 million or 4.7% of the
increase for the quarter. Our overall year-over-year growth rate for the
Cardiology sector was approximately 12% for the quarter and year-to-date.
Unit dose sales of Cardiolite(R), a proprietary technetium-based heart
imaging agent to which the Company has preferential U.S. distribution
rights, led the growth in Cardiology with approximately a 15% growth rate
for both the quarter and year-to-date.  We implemented price increases of
approximately 3.5% in both 2000 and 2001, which contributed to the sales
growth.

U.S. MEDICAL IMAGING BUSINESS

Our Medical Imaging business continues to grow both as a result of the
acquisition of sites and growth at existing sites.  Overall, sales have
increased year-over-year 48.9% to $39.4 million for the current quarter and
73.6% year-to-date to $116.2 million.  Same-store sales growth for the three
months ended September 30, 2001 was approximately 8% or $1.9 million and
represented 14.7% of the increase. Same store sales growth year to date was
approximately 13% and represented 13.0% of the increase. Sales associated
with prior acquisitions were responsible for the remainder of the growth.
At quarter end, we had 65 domestic imaging centers compared to 55 for the
comparable quarter in 2000. We expect to continue to grow this business
through a combination of growth in existing sites and acquisitions in
certain strategic geographic regions.  In order to accomplish these goals,
we continue to devote capital for key strategic systems initiatives,
equipment upgrades and replacements at imaging centers, and the purchase of
new imaging equipment such as PET scanners.

INTERNATIONAL OPERATIONS

Our international operations continue to grow and sales increased
year-over-year 48.6% to $12.1 million for the current quarter and 33.6%
year-to-date to $33.4 million. Same-store growth was 3.4% for the
quarter and was again impacted by Taiwan sites, which continued to report
lower sales due to a slowdown in government healthcare funding. Excluding
Taiwan, same-store sales growth was 6.8% for the quarter.  We generated $9.2
million of additional revenues for the nine months ended September 30, 2001
from sites that we opened ourselves and acquired. We look for the continued
expansion of this segment as our existing operations mature and we complete
further strategic acquisitions.

GROSS PROFIT
____________

Gross profit for the three months ended September 30, 2001 increased year-
over-year 31.3% or $17.4 million to $72.8 million.  Year-to-date gross
profit increased year-over-year by 32.0% or $51.8 million to $213.7
million. As a percentage of net sales, gross margins reached 37.6% for the
third quarter ended September 30, 2001 and 38.0% year-to-date compared to
35.6% and 35.3% for the respective periods in 2000.

U.S. PHARMACY SERVICES BUSINESS

The gross profit for the pharmacy services business continues to improve.
Our margin increased from 27.9% or $33.8 million in the third quarter of
2000 to 29.0% or $41.2 million in the third quarter of 2001.Year to date,
this margin increased from 28.4% or $104.4 million in 2000 to 29.4% or
$121.4 million in 2001.  These improvements are due to price increases on
products, the shift from lower margin products to Cardiolite(R) and continued
leverage of our labor and material resources.

<PAGE>

U.S. MEDICAL IMAGING BUSINESS

The gross profit margin for this group decreased from 69.6% or $18.4
million to 66.6% or $26.2 million in the third quarter of 2001 as compared
to the third quarter of 2000.  Year to date, this margin decreased from 70.5%
or $47.2 million in 2000 to 66.7% or $77.6 million in 2001.  This decline is
principally from two factors. The first is the increase in the number of
multi-modality sites as compared to the previous year. We increased the number
of multi-modality sites from twelve at June 30, 2000 to twenty-five at
September 30, 2001 because many local insurance groups prefer to contract with
imaging centers that offer all modalities.  Consequently, insurance groups do
not have to enter into multiple contracts.  Our multi-modality sites generally
have a lower gross profit margin due to lower average scan fees and higher
operating costs. The second reason for the margin decline is that we
experienced an increase in reading fees that we pay to our contracted
radiologists.

INTERNATIONAL OPERATIONS

The gross profit margin for this segment increased from 40.5% or $3.3 million
to 44.5% or $5.4 million in the third quarter of 2000 as compared to the
third quarter of 2001.  Year to date, this margin increased from 41.6% or
$10.4 million in 2000 to 44.3% or $14.8 million in 2001. These margins have
improved as volumes increase and efficiencies improve at our pharmacy sites.
Our overall mix of revenues from imaging centers has also contributed to
higher margins, as imaging margins are traditionally higher than pharmacy
margins.

OPERATING, SELLING AND ADMINISTRATIVE EXPENSES
______________________________________________

Operating, Selling and Administrative costs increased 30.1% or $10.9
million for the third quarter of 2001 as compared to the third quarter of
2000.  These costs increased 26.5% or $26.8 million on a year-to-date
basis. The ratio of these expenses to sales increased slightly to 24.3%
from 23.3% in the comparative quarter in 2000. Year-to-date, these costs
increased from 22.0% in 2000 to 22.7% in 2001. The primary reason this
percentage remained relatively flat in the quarter and year-to-date was
that we accrued bonuses, which are linked to reaching certain stock price
and earnings levels at a higher rate during 2000 than in 2001. These
smaller accrued bonus amounts were offset in the current year by increased
headcount, yearly wage increases, and increases in other expenses.

DEPRECIATION AND AMORTIZATION
_____________________________

Depreciation and amortization increased by 48.4% or $3.4 million to $10.3
million for the third quarter 2001 as compared to the third quarter of
2000.  These costs increased 49.7% or $9.3 million to $28.0 million on a
year-to-date basis.  These increases were primarily the result of
depreciation, goodwill and non-compete costs associated with our imaging
business acquisitions, which accounts for $2.1 million of this increase for
the quarter and $6.5 million year-to-date.  Additionally, we have invested
capital in international sites (primarily imaging equipment), which
contributed about $1.2 million of this increase on a year-to-date basis.

OTHER EXPENSE, NET
__________________

The increase in Other Expense, Net of $6.2 million to $10.1 million on a
year-to-date basis was primarily the result of increased interest expense for
acquisition debt incurred since the prior year offset by lower interest rates
on the variable portion of the debt.

ACAUISITION OF BUSINESSES
_________________________

During the third quarter of 2001, we made four acquisition investments. We
acquired a company that provides cardiovascular services through three
sites in North Carolina and Virginia for a purchase price of $13.8 million.
We also acquired a domestic company that designs, manufactures and sells
radiation detection and measurement equipment for the medical and nuclear
power plant industry for a purchase price of $10.8 million. In addition,
our medical imaging business acquired three centers via two acquisitions in
the quarter. The first of these was a multi-MRI site in Ft. Lauderdale,
Florida for a purchase price of $5.1 million plus the assumption of $1.5
million of debt. Secondly we acquired two MRI centers in El Paso, Texas for
a purchase price of $4.3 million plus the assumption of $3.6 million of
debt.

<PAGE>

LIQUIDITY AND CAPITAL RESOURCES
_______________________________

We had cash, cash equivalents and investments of $38.1 million at September
30, 2001 compared with $42.0 million at December 31, 2000.  Our total debt
of $230.9 million at September 30, 2001 reflects an increase of $80.9
million when compared to the balance of $150.0 million at December 31,
2000.  The increase for the nine months ended September 30, 2001 results
primarily from the financing of acquisitions, which required approximately
$52.0 million and capital additions, which exceeded cash provided by
operations by $4.1 million. In addition, since December 31, 2000, we
repurchased 411,000 shares of our stock at a value of $13.9 million for
treasury stock.  Working capital increased by $52.1 million to $132.5
million at September 30, 2001 compared to $80.4 million at December 31,
2000. We believe that sufficient internal and external sources exist to
fund operations and future expansion plans.  We have $21.3 million in
available credit on the $200 million credit line at September 30, 2001.


FORWARD-LOOKING STATEMENTS
__________________________

Except for the historical information and discussions contained herein,
statements contained in this Report on Form 10-Q may constitute "forward
looking statements" within the meaning of the Private Securities Litigation
Reform Act of 1995.  These statements involve a number of risks,
uncertainties and other factors that could cause actual results to differ
materially, including: changes in the regulation of the healthcare industry
at either or both of the federal and state levels; changes or delays in
reimbursement for our services by governmental or private payers; our
failure to continue to develop and market new products and services and to
keep pace with technological change; competitive pressures; failure to
obtain or protect intellectual property rights; quarterly fluctuations in
revenues and volatility of our stock price; our ability to attract and
retain key personnel; currency risks; dependence on certain suppliers; our
ability to successfully manage acquisitions and alliances; legal, political
and economic changes; and other risks, uncertainties and factors discussed
in the "Risk Factors" section in the Annual Report on Form 10-K and
elsewhere herein, in our other filings with the SEC or in materials
incorporated by reference.  Given these uncertainties, undue reliance
should not be placed on such forward-looking statements.


ITEM 3.


QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS
___________________________________________________________

Interest income earned on our investment portfolio is affected by changes
in the general level of U.S. interest rates. Our line of credit borrowings
effectively bear interest at variable rates and therefore, changes in U.S.
interest rates affect interest expense incurred thereon. Changes in
interest rates do not affect interest expense incurred on our fixed rate
debt. There have been no significant changes in the debt instruments from
the table as filed on December 31, 2000.

<PAGE>

           SYNCOR INTERNATIONAL CORPORATION AND SUBSIDIARIES



Part II.  OTHER INFORMATION

Item 6.     Exhibits and Reports on Form 8-K

(a)     Exhibits

10.     Material Contracts

     10.1   First Amendment to First Amended and Restated Credit Agreement
            dated as of September 13, 2001, among Bank One, NA as Lender,
            The Bank of Nova Scotia as Document Agent, the Company and Syncor
            Management Corporation
     10.2   Severance Agreement dated August 24, 2001 between Haig
            Bagerdjian and the Company
     10.3   Severance Agreement dated August 24, 2001 between John S.
            Baumann and the Company
     10.4   Severance Agreement dated August 24, 2001 between Rodney
            Boone and the Company
     10.5   Severance Agreement dated August 24, 2001 between Jack Coffey
            and the Company
     10.6   Severance Agreement dated August 24, 2001 between Sheila Coop
            and the Company
     10.7   Severance Agreement dated August 24, 2001 between William
            Forster and the Company
     10.8   Severance Agreement dated August 24, 2001 between Monty Fu
            and the Company
     10.9   Severance Agreement dated August 24, 2001 between Robert
            Funari and the Company
     10.10  Severance Agreement dated August 24, 2001 between Lewis William
            Terry, Jr. and the Company
     10.11  Severance Agreement dated August 24, 2001 between David Ward
            and the Company
     10.12  Syncor International Corporation Special Severance Plan

11.     Statement re:  Computation of Per Share Earnings

        Computation can be clearly determined from the material contained in
        Part I of this Form 10-Q.


<PAGE>

                                 SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.


                              SYNCOR INTERNATIONAL CORPORATION
                                        (Registrant)





November 14, 2001           By:  /s/ William P. Forster
                            _________________________________________________
                            William P. Forster
                            Senior Vice President and Chief Financial Officer
                            (Principal Financial/Accounting Officer)